Mammalian Display video
Fusion Antibodies plc is announcing the upcoming commercial launch of its OptiMAL® Human Antibody Discovery platform, featuring a video explaining its Mammalian Display technology, which boasts over 70% transduction efficiency and supports libraries exceeding 10⁹ variants, significantly outperforming competitor platforms. The company will also host a pre-recorded presentation and Q&A session on December 16, 2025, to discuss the launch, with no new material information expected. Investors are encouraged to submit questions via the company's Investor Hub.
Select text to share a quote on X · sign in to keep highlights & notes in your FAB notes
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that ahead of the commercial launch of the OptiMAL® Human Antibody Discovery platform at the Antibody Engineering and Technology conference in San Diego on 15 December 2025, Fusion has prepared a short video of Dr Richard Buick, CSO, explaining some of the features, science and technology behind the Company's Mammalian Display technology. The technology has been combined with Fusion's Opti-library to create the OptiMAL® library. OptiMAL® is intended to be used to discover novel human antibodies against any target. The mammalian display platform library design and method is protected by US patent US12378696. The Mammalian Display technology can also be used with other antibody libraries.
The video can be viewed on the Investor Hub section of Fusion's website at, https://investorhub.fusionantibodies.com/s/7ea305.
Other Mammalian Display technologies are available and have been summarised in the scientific literature e.g. Slavny P, Hegde M, Doerner A, Parthiban K, McCafferty J, Zielonka S and Hoet R (2024) Advancements in mammalian display technology for therapeutic antibody development and beyond: current landscape, challenges, and future prospects. Front. Immunol. 15:1469329. doi: 10.3389/fimmu.2024.1469329.
Fusion Antibodies has compared its own Mammalian Display technology to the competitor platforms in the review article and identified several superior advantages. The most significant are its transduction efficiency of over 70% and its ability to support very large libraries, exceeding 10⁹ variants. These are summarised in the table below:
| Technology | OptiMAL ® | Retrocyte Display | Other Lentiviral mammalian display | Transposase-mediated integration | Nuclease-directed integration | Recombinase-mediated integration |
|---|---|---|---|---|---|---|
| Integration Efficiency | >70% | <5% | 0.5-5% | 6-7.5% | 0.5-5% | 1.7% |
| Reported library sizes | >10 9 | 10 6 -10 8 | 10 6 | 10 6 | 10 6 -10 8 | 10 6 -10 8 |
If shareholders or prospective investors have further queries regarding the Mammalian Display platform, please submit questions you may have regarding this update using the facility provided.
Investor Presentation and Q&A: OptiMAL® Launch
Adrian Kinkaid, CEO of Fusion will provide a pre-recorded presentation and Q&A session on the OptiMAL® launch from the Antibody Engineering & Therapeutics Conference via the Company's Investor Hub on Tuesday, 16 December 2025, at 16:00 GMT.
The presentation is open to all existing and potential shareholders. Questions are encouraged and can be pre-submitted via the webinar page.
Register and submit your questions here: https://investorhub.fusionantibodies.com/webinars/mPqXOr-optimal-r-launch-investor-q-a
No material new information will be included in the presentation or Q&A.
Fusion Antibodies wants to keep its investors up to date with developments in the Company technology and offerings. We have therefore created a space on the Investor Hub which in contains an increasing number of videos providing more information which may be of interest to investors. This can be found here, https://investorhub.fusionantibodies.com/s/1b6535.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.